Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

NCT07180160 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

123

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: QL1706
DRUG: CDK4/6 inhibitor
DRUG: Fulvestrant

Sponsor

Wenjin Yin